摘要
目的:观察托吡酯治疗结节性硬化症合并癫痫患儿的临床疗效。方法:将诊断明确的7例结节性硬化症合并癫痫患儿用托吡酯治疗,用药24周后评价其疗效。结果:接受托吡酯治疗的最小剂量是2.2mg/(kg·d),最大剂量5.0mg/(kg·d),平均剂量是4.2mg/(kg·d)。用药24周后6例患儿癫痫发作均得到不同程度的控制,其中2例完全控制,显效(发作频率减少>75%)3例,有效(发作频率减少>50%)2例;治疗后半年所有病例脑电图有不同程度的改善,2例面部血管纤维瘤逐渐消退。结论:托吡酯对结节性硬化症合并癫痫患儿有较好的疗效,且有助于改善结节性硬化症的面部血管纤维瘤等症状。
Objective：To observe and evaluate the clinical efficiency of topiramate for treatment of epileptic children with tuberous sclerosis. Methods： 7 epileptic children with tuberous sclerosis underwent the treatment of topiramate, The efficiency was evaluated after 24 weeks＇ treatment. Results： The minimum dose of topiramate was 2.2 mg/（kg·d）, the maximum dose was 5,0 mg/（kg·d）, and the mean dose was 4.2 mg/（kg·d）. After 24 weeks＇ treatment, the frequency of seizures reduced differently： 2 cases were completely controlled, 3 cases were reduced 〉75%, 2 cases were reduced 〉 50%. After half a year＇ s treatment, the EEG of all cases was improved and facial angiofibromas in 2 cases became extinct gradually. Conclusions： Topiramate is effective to epileptic patients with tuberous sclerosis and conduce to facial angiofibromas.
出处
《儿科药学杂志》
CAS
2007年第2期30-32,共3页
Journal of Pediatric Pharmacy
关键词
托吡酯
结节性硬化症
癫痫
Topiramate
Tuberous sclerosis
Epilepsy
